ClinicalTrials.gg
CompletedNCT00909883RBHP 2008Updated Nov 9, 2026

Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)

A Phase 3 interventional study of Botulinum Toxin: Xeomin and Placebo in Parkinson's Disease and Foot Dystonia, sponsored by University Hospital, Clermont-Ferrand. Completed at 4 sites in France. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Phase 3, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedResults publication added+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand — 5 open to participants now, 5 under way, none of them phase 3. Parkinson Disease · University Hospital, Clermont-Ferrand.

Enrollment
13th of 23
45 · median 46
Started
2010
with 2 others
Phase 3
Only one
of the 25
Registered
4th of 25
by date

Among the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, this one is the 13th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2010, is the only one in phase 3, and was the 4th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Parkinson Disease by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

Foot dystonia is frequently observed in patients suffering from Parkinson'disease. It is characterized by an abnormal involuntary movement which is very uncomfortable (difficult to walk) and painful for the patient.

Botulinum toxin injections seem to be efficient to treat this dystonia. However studies on this topic are few and very imprecise (many muscle injected, especially the Flexor digitorum longus, different doses used, heterogeneous population with many types of dystonia included, open studies).

Read the detailed description

Study progress :

After an inclusion visit, patients are randomized in one of the 3 following groups :

  • First group (PL : placebo) :

    • J0 : Patient will receive 1 injection of placebo in the Flexor digitorum longus and 1 injection of placebo in the Flexor digitorum brevis or in the quadratus plantae
    • J+1month : First evaluation
    • J+3 months : Patient will receive again 1 injection of placebo in the Flexor digitorum longus and 1 injection of placebo in the Flexor digitorum brevis or in the quadratus plantae
    • J+4 months : Last evaluation
  • Second group (ME : Extrinsic muscle)

    • J0 : Patient will receive 1 injection of Botulinum toxin (100U) in the Flexor digitorum longus and 1 injection of placebo in the Flexor digitorum brevis or in the quadratus plantae
    • J+1 month : First evaluation
    • J+3 months : Patient will receive again 1 injection of Botulinum toxin (100U) in the Flexor digitorum longus and 1 injection of placebo in the Flexor digitorum brevis or in the quadratus plantae
    • J+4 months : Last evaluation
  • Third group (MI : Intrinsic muscle)

    • J0 : Patient will receive 1 injection of placebo in the Flexor digitorum longus and 1 injection of Botulinum toxin (100U) in the Flexor digitorum brevis or in the quadratus plantae
    • J+1 month : First evaluations
    • J+3 months : Patient will receive again 1 injection of placebo in the Flexor digitorum longus and 1 injection of Botulinum toxin (100U) in the Flexor digitorum brevis or in the quadratus plantae
    • J+4 months : Last evaluations

During injections (J0 and J+3M), we will measure the pain induced by injections (EVA) For each evaluation (J+1M and J+4M), following evaluations will be made: clinical improvement (CGI), dystonia evaluation (duration and severity, Burke scale), pain (EVA) and quality of life (PDQ39).

03

Conditions studied

  • Parkinson's Disease
  • Foot Dystonia

Keywords

  • Idiopathic Parkinson's disease
  • Foot (Tiptoe) dystonia
  • Botulinum Toxin
  • Muscles : Flexor digitorum longus/ Flexor digitorum brevis/ quadratus plantae
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age : 30-75 years
  • Patient with an idiopathic Parkinson's disease according to the criteria of the "Parkinson's Disease Society Brain Bank"
  • Patient with unilateral tiptoe dystonia. Dystonia must be present more than 1h /day and induce difficulties to walk (severity index ≥ 3 (1 : light, 2 : moderate, 3 : severe, 4 : very severe)).
  • Patients never treated with botulinum toxin or already treated for more than 6 months.
  • Affiliation to social security
  • Agreement of patients

Exclusion criteria

Exclusion Criteria:

  • Patients suffering of an atypical Parkinson syndrome
  • Patient with a bilateral tiptoe dystonia
  • Patients with to the botulinum toxin use
  • Women without efficient
  • Person who participate to an other study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. In a controlled double blind and randomized study, we want to show that intramuscular injections of botulinum toxin are beneficial to reduced dystonia and associated pain in patient with foot dystonia (compared to placebo injections).

    Time frame: one month after the injection of botulinum toxin/placebo

Secondary outcomes

  1. Efficiency comparison of injections made in leg muscle (Flexor digitorum longus) between injections made directly in foot muscle (Flexor digitorum brevis or quadratus plantae) - Effects of injections on pain and quality of life.

    Time frame: one month after injections of placebo or Botulinum toxin

07

Study locations

4 sites
  • CHU Purpan
    Toulouse, Toulouse 31059, France
  • CHU Gabriel-Montpied
    Clermont-Ferrand, 63003, France
  • Hôpital La Pitié Salpétrière
    Paris, 75651, France
  • Hôpital Haut-Levêque
    Pessac, 33600, France
08

References and documents

Publications

  • Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluchere F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouhour F, Llinares E, Derost P, Marques A, Durif F. Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial. Parkinsonism Relat Disord. 2018 Jan;46:9-15. doi: 10.1016/j.parkreldis.2017.10.009. Epub 2017 Oct 19. PubMed 29102441 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Nov 2013, 44 months.

Of 68 phase 3 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 44 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Sep 2009 → Feb 2010, primary completion Sep 2011 → Nov 2013 and completion Sep 2012 → Feb 2014.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2009
First posted
May 29, 2009
StartActual
Feb 22, 2010was Sep 2009
Primary completionActual
Nov 12, 2013was Sep 2011
CompletionActual
Feb 12, 2014was Sep 2012
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 9, 2026
Sites
1 site added, 1 site removed
Show site
  • CHU Purpan · Toulouse, France
Show 1 removed
  • CHU Purpan · Toulouse, France
Nov 9, 2026
Start date
Sep 2009→Feb 22, 2010 (actual)
Nov 9, 2026
Primary completion
Sep 2011→Nov 12, 2013 (actual)
Nov 9, 2026
Study completion
Sep 2012→Feb 12, 2014 (actual)
Nov 9, 2026
Publications
Results publication added: Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluchere F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouho… PubMed 29102441 ↗
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Status unknown→Completed
    Publications Results publication added: Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluchere F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouho… PubMed 29102441 ↗
    1 site added, 1 site removed
    Show site
    • CHU Purpan · Toulouse, France
    Show 1 removed
    • CHU Purpan · Toulouse, France
    Start date Sep 2009→Feb 22, 2010 (now actual)
    Primary completion Sep 2011→Nov 12, 2013 (now actual)
    Study completion Sep 2012→Feb 12, 2014 (now actual)
    + 3 other changes: verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00909883
Collaborators
Merz Pharmaceuticals
Responsible party
Sponsor
First posted
May 29, 2009
Start date
Feb 22, 2010
Primary completion
Nov 12, 2013
Completion
Feb 12, 2014
Last update
Nov 9, 2026

Study contacts

Franck Durif
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion